Artificial Coma Market Expected to Reach $868.63 Million by 2030 | CAGR of 3.1%

According to a new report published by Allied Market Research, titled, “Artificial Coma/Medically Induced Coma Market by Drug Type, Application, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021–2030,"the artificial coma market size was valued at $640.17 Million in 2020, and is projected to reach $868.63 Million by 2030, registering a CAGR of 3.1%.

Medical induced coma is defined as the situation that inactivates brain for some time to get relief. An anesthesiologist starts a medically induced coma, which specializes in relieving pain and providing the best medical care for patients before or during a surgical procedure. Medically induced coma is also known as drug induced coma and artificial coma. Once, the artificial coma is underway, Intensive Care Unit staff will monitor brain activity. Drug induced comas are ICU procedures. ICUs have the required equipment to support airway and monitor the function of heart rate, blood pressure and respiratory condition. The anesthesiologist gives drugs to patients to induce coma. It includes drugs such as barbiturate and propofol. This powerful anesthetics will take the brain into a state of unconsciousness.

The factors that drive the growth of the artificial coma market include rise in prevalence of chronic and infectious disease such as hypertension, cancer, cardiovascular disease, and diabetes; increase in geriatric population; advancement in technology in healthcare sectors; and surge in demand for anesthetic drugs.

In January 2020, Lannett Company received the Food and Drug Administration approval for the drug cocaine hydrochloride, a nasal solution for anesthetic use in the U.S. Moreover, in June 2021, PAION AG has received the UK Medicines & Healthcare products Regulatory Agency approval for Byfavo (remimazolam besylate) in adults for induced coma during surgical procedure. For Instance, in August 2021, researchers from University of Michigan and Washington University School of Medicine in St. Louis conducted a study for anesthetic drugs, which will improve clinical outcomes. This study involves anesthetic drugs such as intravenous propofol. Researchers are focusing on R&D activities for anesthetic medications that are used to induce coma in patients during their critical surgical interventions.

According to the United Nations Department of Economic and Social Affairs, by 2050, one in four people living in Europe and North America could be aged 65 years or above. The increase in prevalence of older population has led to a steep rise in the number of chronic diseases among elderly people, further leading to the rising demand for anesthetic drugs. Rise in demand to reduce pain during surgery, advancement in R&D activities in pharmaceutical and biotechnology industry, and surge in the number of surgeries are anticipated to drive the growth of the artificial coma/medically induced coma market. In addition, development of innovative medications in the healthcare sector, are thereby propelling the growth of the market.

Moreover, initiatives taken by governments for the approval of drugs and tremendous increase in number of anesthetic medications are the key factors that boost the growth of the market. For instance, in January 2019, Sandoz, a division of Novartis has launched Desflurane Liquid for Inhalation; it is the first generic of Suprane liquid by Baxter healthcare in the U.S. It is used for the management of artificial coma during surgery in adults.

As per the article published by Neurology India the overall incidences of stroke in Asia varied between 116 and 483/100,000 per year. Stroke incidences in the younger individuals has increased globally, with higher physical consequences. Whereas, traumatic brain injury is the leading cause of damage the brain tissues. In India, it falls with an incidences three times that of overall global rate (13.3 per 100,000). Therefore, rising burden of injuries leads to increase in number of surgeries and is expected to drive the artificial coma market growth. 

The artificial coma market is segmented on the basis of drug type, application, distribution channel, and region. On the basis of drug type, the market is divided into propofol and barbiturate. The propofol segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in use of drugs during surgery and development in healthcare sector.

On the basis of application, the market is classified into status epilepticus, stroke traumatic brain injury, brain infections, drug overdose and others. The stroke segment dominated the artificial coma market in 2020, and is expected to continue this trend during the forecast period, owing to increase in prevalence of chronic diseases, neurological disorders, cardiovascular; and advancement in R&D for drug discovery and development activities. On the basis of distribution channel, the artificial coma market is classified into hospital pharmacies, drug stores & retail pharmacies. The hospital pharmacies segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in number of drug stores.

Key Findings of the Study

• By drug type, the stroke segment was the highest contributor to the market in 2020.
• On the basis of application, the stroke segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
• Depending on distribution Channel, the hospital pharmacies segment was the highest contributor to the artificial coma market in 2020.
• Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

North America accounted for a majority of the global medical induced coma market share in 2020 and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of traumatic brain injury and increase in number of cases of disorders, which are caused by drug overdose, and advancement for new drug innovation. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in prevalence of stroke and rise in number of key players.